Abliva AB
STO:ABLI

Watchlist Manager
Abliva AB Logo
Abliva AB
STO:ABLI
Watchlist
Price: 0.444 SEK 0.23% Market Closed
Market Cap: 715.7m SEK

Abliva AB
Investor Relations

Abliva AB is a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of primary mitochondrial diseases. The company is headquartered in Lund, Skane. The company went IPO on 2008-10-03. The firm focuses on the development of novel treatments for primary mitochondrial diseases.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Dr. Ellen K. Donnelly Ph.D.
Chief Executive Officer
No Bio Available
Ms. Catharina Jz Johansson
Deputy CEO, CFO & VP of Investor Relations
No Bio Available
Dr. Eskil Elmér M.D., Ph.D.
Chief Scientific Officer & VP of Discovery
No Bio Available
Ms. Eleonor Åsander Frostner
Communications Officer & Lab Manager
No Bio Available
Dr. Magnus Hansson
Chief Medical Officer and VP of Preclinical & Clinical Development
No Bio Available
Mr. Dag Nesse
Vice President of Clinical Operations
No Bio Available
Dr. Lars Vedin
Consultant
No Bio Available

Contacts

Address
SKANE
Lund
Medicon Village, Scheeletorget 1
Contacts
+46462756220.0
abliva.com